Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.

Hey JA, Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada M, Doraiswamy PM, Elahi FM, Rissman RA, Liang E, Flint S, Hristova E, Kesslak P, McLaine R, Albayrak A, Schaefer JF, Yu JY, Tolar L, Tolar M

Open source

DOI: 10.1007/s40265-026-02381-3
Published: 2026 Sep 1
Container: Drugs
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40265-026-02381-3,
  title = {Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.},
  author = {Hey JA and Abushakra S and Power A and Watson D and Porsteinsson A and Sabbagh M and MacSweeney E and Cohen S and Boada M and Doraiswamy PM and Elahi FM and Rissman RA and Liang E and Flint S and Hristova E and Kesslak P and McLaine R and Albayrak A and Schaefer JF and Yu JY and Tolar L and Tolar M},
  year = {2026},
  journal = {Drugs},
  doi = {10.1007/s40265-026-02381-3},
  url = {https://doi.org/10.1007/s40265-026-02381-3}
}

RIS

TY  - JOUR
TI  - Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.
AU  - Hey JA
AU  - Abushakra S
AU  - Power A
AU  - Watson D
AU  - Porsteinsson A
AU  - Sabbagh M
AU  - MacSweeney E
AU  - Cohen S
AU  - Boada M
AU  - Doraiswamy PM
AU  - Elahi FM
AU  - Rissman RA
AU  - Liang E
AU  - Flint S
AU  - Hristova E
AU  - Kesslak P
AU  - McLaine R
AU  - Albayrak A
AU  - Schaefer JF
AU  - Yu JY
AU  - Tolar L
AU  - Tolar M
PY  - 2026
JO  - Drugs
DO  - 10.1007/s40265-026-02381-3
UR  - https://doi.org/10.1007/s40265-026-02381-3
ER  -

APA

JA, H., S, A., A, P., D, W., A, P., M, S., E, M., S, C., M, B., PM, D., FM, E., RA, R., E, L., S, F., E, H., P, K., R, M., A, A., JF, S., JY, Y., L, T., & M, T. (2026). Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.. Drugs. https://doi.org/10.1007/s40265-026-02381-3

Source records

pubmed · retrieved 2026-09-25T15:00:14.580Z